ArQule's lead development project set for Phase III lung cancer trial
This article was originally published in Scrip
Executive Summary
ArQule and licensee Daiichi Sankyo are preparing to begin a Phase III clinical trial programme with ArQule's most advanced product candidate, the c-Met receptor tyrosine kinase inhibitor ARQ 197, for the treatment of non-small cell lung cancer (NSCLC).